Immunicum includes first patient in a phase II study in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immunicum includes first patient in a phase II study in patients with metastatic kidney cancer

Gothenburg, Sweden, 2015-05-05 09:01 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the first patient has been included in the international phase II study with the therapeutic cancer vaccine INTUVAX for the treatment of patients with metastatic kidney cancer.

INTUVAX is a therapeutic cancer vaccine, based on blood components from healthy donors, that has been developed for treating patients with solid tumors. The phase II study, MERECA (MEtastatic REnal cell CArcinoma), has been designed on the basis of the promising results obtained in a phase I/II trial in patients with metastatic renal cell cancer.

Immunicum plans to include a total of 90 patients at 20 European centers. INTUVAX is injected in the primary tumors at two occasions before a surgical removal of the kidney with the primary tumor. Patients will be randomized (randomly distributed) 2:1 between either INTUVAX in combination with sunitinib or only sunitinib, an approved drug for the treatment of kidney cancer.

The study will include 60 % patients with intermediate-risk prognosis and 40 % patients with high-risk prognosis. Patients will be monitored for 18 months with the primary objective to evaluate the median overall survival in high-risk prognosis patients. Patients in the treatment arm with a high-risk prognosis receive INTUVAX and will subsequently receive add-on treatment with sunitinib beginning six weeks after surgery, while patients in the treatment arm with intermediate-risk prognosis receive INTUVAX as monotherapy with subsequent add-on therapy with sunitinib only when/if the disease shows signs of progression.

- The open design of the MERECA study gives us continuous valuable information about the efficacy and safety of INTUVAX. It facilitates planning of future studies and increases the scope for a possible earlier out-licensing of the project. Of course, the market will also continuously be updated on efficacy and safety data when information is deemed relevant, says Immunicum’s CEO Jamal El-Mosleh.

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum

Phone: +46 (0) 31 41 50 52 jamal.el-mosleh@immunicum.com

Alex Karlsson-Parra, CSO, Immunicum

Phone: +46 (0) 705 16 75 79

alex.karlsson-parra@immunicum.com

The company’s Certified Adviser is Redeye AB

Phone: +46 (0) 8 545 013 31. www.redeye.se

About Immunicum AB (publ)

Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A phase II study of the Company's most advanced project - INTUVAX® against renal cancer – has been initiated. The project portfolio contains an additional clinical phase I/II project in liver cancer.

www.immunicum.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 291

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 321

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 139

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 201

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 192

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 249

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 298

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 193

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 158

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 190

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding State Resilience Against Future Economic Challenges

Updated Category News Views 119

States Vulnerable to Economic Downturns The landscape of economic stability is shifting, and many residents might be unaware of how their home states rank in terms of recession preparedness. Recent analyses reveal striking differences in resilience that could significantly impact everyday Americans. With numerous warnings about incoming economic turbulence, it’s crucial...

Continue Reading
Liquidia's Milestone Funding for YUTREPIA™ Sales Surge

Updated Category News Views 334

Liquidia Corporation Announces Significant Funding Boost Liquidia Corporation (NASDAQ: LQDA), a prominent biopharmaceutical company, is thrilled to announce that it has secured an additional $50 million to support the launch of its innovative treatment, YUTREPIA™. This exciting development follows a pivotal legal victory where a U.S. District Court ruled against a...

Continue Reading
Paratus Energy Services Ltd. Reports Mandatory Trade Update

Updated Category News Views 189

Paratus Energy Services Ltd. Reports Mandatory Trade Notification Paratus Energy Services Ltd. has recently announced a significant trade notification involving a close associate of one of its board members. The company, which operates in the energy sector, has revealed that a fund managed by Lodbrok Capital LLP has completed a trade involving its shares. This information...

Continue Reading
Angel Launches Global Theatrical Release of David Musical

Updated Category News Views 181

Angel's Global Release of David Musical Animated musical builds powerful momentum as early domestic pre-sales surge close to $6 million Angel (NYSE: ANGX), a leading media and technology company championing values-driven stories, is setting the stage for the theatrical release of the eagerly awaited animated musical David across 43 international markets. This significant...

Continue Reading
LifeMD, Inc. Announces Exciting Dividend for Shareholders

Updated Category News Views 116

LifeMD, Inc. Announces Quarterly Dividend LifeMD, Inc. (NASDAQ: LFMD), recognized for its pioneering virtual primary care offerings, has announced an important cash dividend for its shareholders. The Company's Board of Directors has declared a cash dividend of $0.5546875 per share on the 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ: LFMDP). This...

Continue Reading